BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/24/2026 6:23:42 AM | Browse: 1 | Download: 0
 |
Received |
|
2026-04-22 05:59 |
|
Peer-Review Started |
|
2026-04-22 05:59 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2026-06-23 03:15 |
|
Revised |
|
2026-06-30 17:47 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-08-03 02:09 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-08-28 09:17 |
|
Articles in Press |
|
2026-08-28 09:17 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-09-20 02:02 |
|
Publish the Manuscript Online |
|
2026-09-24 06:23 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cell & Tissue Engineering |
| Manuscript Type |
Review |
| Article Title |
Induced pluripotent stem cell-derived chimeric antigen receptor natural killer cells: Engineering innovations, translational hurdles and clinical prospects in immune therapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xu-Lin Liu, Si-Min Han, Gang-Hui Ye, Qing-Lu Wang, Ying Luo and Yan-Mei Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Zhejiang Medical Health Science & Technology Project |
2022KY1403 |
| Natural Scientific Foundation of Shandong Province |
ZR2025MS1369 |
|
| Corresponding Author |
Ying Luo, MD, PhD, Department of Clinical Laboratory, Zibo Central Hospital, No. 54 Gongqingtuan West Road, Zhangdian District, Zibo 255000, Shandong Province, China. luoying1242@126.com |
| Key Words |
Induced pluripotent stem cells; Chimeric antigen receptor natural killer cells; Off-the-shelf immunotherapy; Cell engineering; Clinical translation; Tumor microenvironment; Genome editing; Synthetic biology |
| Core Tip |
Induced pluripotent stem cell-derived chimeric antigen receptor (CAR) natural killer cells provide a candidate standardized, cell-bank-driven platform for off-the-shelf immunotherapy. Their translational value should not be judged solely by CAR expression, enhanced cytotoxicity, or accumulated engineering modules. This review proposes a multilevel framework integrating product definition, effector execution, tissue delivery, host interaction, and translational implementation, and emphasizes dominant bottlenecks, evidence levels, engineering trade-offs, and the gap between preclinical functional enhancement and established clinical benefit. |
| Publish Date |
2026-09-24 06:23 |
| Citation |
Liu XL, Han SM, Ye GH, Wang QL, Luo Y, Liu YM. Induced pluripotent stem cell-derived chimeric antigen receptor natural killer cells: Engineering innovations, translational hurdles and clinical prospects in immune therapy. World J Stem Cells 2026; 18(9): 122513
|
| URL |
https://www.wjgnet.com/1948-0210/full/v18/i9/122513.htm |
| DOI |
https://doi.org/10.4252/wjsc.122513 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
